[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619796":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University of Thi-Qar","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Preeclampsia - No Antihypertensive Treatment",null,"This group includes pregnant women diagnosed with preeclampsia. Blood samples are collected at the time of diagnosis before starting any antihypertensive treatment. All participants will receive standard clinical care after sample collection. Samples will be processed, aliquoted, and stored at -80°C for biomarker analysis (sFlt-1, PlGF, soluble endoglin, and osteoprotegerin).",{"label":13,"type":10,"description":14,"interventionNames":10},"Preeclampsia - With Antihypertensive Treatment","is group includes pregnant women diagnosed with preeclampsia who are receiving standard antihypertensive therapy as part of their clinical care. Blood samples (5 mL) will be collected for measurement of biomarkers (sFlt-1, PlGF, sEng, OPG). Samples will be processed, aliquoted, and stored at -80°C. Clinical parameters and treatment details will also be recorded for analysi",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy Pregnant Controls","his group includes healthy pregnant women without preeclampsia. Blood samples (5 mL) will be collected to serve as controls for biomarker analysis. Samples will be processed, aliquoted, and stored at -80°C. Participants will receive routine prenatal care.",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Ammar Jassim Abed, MSc","CONTACT","+9647809561105","ammar.jassim11@gmail.com",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Bint Al Huda Maternity Hospital","RECRUITING","Nasiriyah","Dhi Qar","64001","Iraq","IQ",{"type":34,"coordinates":35},"Point",[36,37],46.25726,31.05799,{"lat":37,"lon":36},[40],{"name":41,"role":21,"phone":42,"phoneExt":10,"email":23},"Ammar Jassim Abed","9647809561105",{"type":44,"investigatorFullName":41,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Master's Student (MSc Researcher), Principal Investigator","100619796","evaluation-of-sflt-1plgf-ratio-opg-and-seng-as-predictive-biomarkers-in-the-diagnosis-and-treatment-evaluation-of-preeclampsia-100619796",false,"NCT07349277","Evaluation of sFlt-1\u002FPlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia","Evaluation of sFlt-1\u002FPlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia","PE-POSS","IInclusion Criteria:\n\n* Pregnant women between 20 and 36 weeks of gestation\n* Age between 18 and 45 years\n* Attending the antenatal clinic at the study site\n\nExclusion Criteria:\n\n* Chronic hypertension\n* Renal disease\n* Diabetes mellitus\n* Multiple gestations\n* Autoimmune disorders",true,"FEMALE","18 Years","45 Years",{"count":59,"type":60},120,"ESTIMATED","OBSERVATIONAL","his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1\u002FPlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide",[64,65,66],"Preeclampsia","Gestational Hypertension","Hypertensive Disorders of Pregnancy",[68,69,70,71,72,64,73],"sFlt-1\u002FPlGF ratio","Soluble Endoglin (sEng)","Osteoprotegerin (OPG)","Angiogenesis","Placental Dysfunction","methyldopa","2026-01-15",{"date":76,"type":77},"2026-01-20","ACTUAL",{"date":79,"type":77},"2025-10-10",{"date":81,"type":60},"2026-04-30",{"name":41,"class":6},1]